SCHEMBL7651463

SCHEMBL7651463

CCc1c[nH]c2ccc(C)cc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 4/20 0.67
HTR2A P28223 3/20 0.67
MTNR1A P48039 1/20 0.59
MTNR1B P49286 1/20 0.59
LMNA P02545 2/20 0.54
RAB9A P51151 1/20 0.54
HTR1B P28222 3/20 0.54
HTR1A P08908 2/20 0.54
ADRA2A P08913 1/20 0.54
DRD2 P14416 1/20 0.54
ADRA2B P18089 1/20 0.54
ADRA2C P18825 1/20 0.54
HTR2C P28335 1/20 0.54
HTR1E P28566 1/20 0.54
SLC6A4 P31645 1/20 0.54
HTR7 P34969 1/20 0.54
ADRA1A P35348 1/20 0.54
HRH1 P35367 1/20 0.54
ADRA1B P35368 1/20 0.54
DRD3 P35462 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19335885 0.87 HTR1D (0.61) HTR1DHTR2AMTNR1AMTNR1BLMNA
SCHEMBL18383116 0.86 HTR1D (0.69) HTR1DHTR2AMTNR1AMTNR1BLMNA
SCHEMBL8344495 0.85 HTR1D (0.73) HTR1DHTR2AMTNR1AMTNR1BLMNA
SCHEMBL12233833 0.85 HTR2A (0.67) HTR1DHTR2AMTNR1AMTNR1BLMNA
SCHEMBL1722931 0.83 HTR1D (0.65) HTR1DHTR2AMTNR1AMTNR1BLMNA
SCHEMBL31567644 0.83 HTR1D (0.65) HTR1DHTR2AMTNR1AMTNR1BLMNA
SCHEMBL24814500 0.81 MTNR1A (0.63) HTR1DHTR2AMTNR1AMTNR1BLMNA
SCHEMBL6116786 0.81 TSHR (0.69) HTR1DHTR2AMTNR1AMTNR1BLMNA
SCHEMBL12013054 0.81 HTR1D (0.73) HTR1DHTR1BHTR1APOLB
SCHEMBL12634153 0.80 HTR1D (0.61) HTR1DHTR2AMTNR1AMTNR1BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023065716-A1 POLYPEPTIDE AND APPLICATION THEREOF AS CCK RECEPTOR AGONIST/ANTAGONIST 中国科学院香港创新研究院再生医学与健康创新中心有限公司 2023-04-27 WO disclosed
US-20220204497-A1 NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2022-06-30 US disclosed
EP-3928804-A2 HYDROGEL INCLUDING SEROTONIN-MODIFIED HYALURONIC ACID AND USE THEREOF Cellartgen Inc. (KR) 2021-12-29 EP disclosed
EP-3892616-A1 AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2021-10-13 EP disclosed
WO-2020114475-A1 AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE 上海济煜医药科技有限公司 2020-06-11 WO disclosed
EP-3330252-B1 ISOPRENYL COMPOUNDS AND METHODS THEREOF SIGNUM BIOSCIENCES INC (US) 2020-02-12 EP disclosed
WO-2019113443-A2 TRYPTOPHAN DERIVATIVES AS SWEETENERS CHROMOCELL CORPORATION (US) 2019-06-13 WO disclosed
EP-3330252-A2 ISOPRENYL COMPOUNDS AND METHODS THEREOF Signum Biosciences, Inc. (US) 2018-06-06 EP disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
WO-2011138665-A1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-11-10 WO disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed
US-20110086001-A1 COMPLIANT BIOCOMPATIBLE POLYMER COMPOSITIONS FOR MEDICAL USES RUTGERS UNIVERSITY (US) 2011-04-14 US disclosed
US-20110086001-A1 COMPLIANT BIOCOMPATIBLE POLYMER COMPOSITIONS FOR MEDICAL USES RUTGERS UNIVERSITY (US) 2011-04-14 US disclosed
US-20100228343-A1 PHASE-SEPARATED BIOCOMPATIBLE POLYMER COMPOSITIONS FOR MEDICAL USES RUTGERS, THE STATE UNIVERSITY (US) 2010-09-09 US disclosed
US-20100228343-A1 PHASE-SEPARATED BIOCOMPATIBLE POLYMER COMPOSITIONS FOR MEDICAL USES RUTGERS, THE STATE UNIVERSITY (US) 2010-09-09 US disclosed
WO-2010042917-A1 PHASE-SEPARATED BIOCOMPATIBLE POLYMER COMPOSITIONS FOR MEDICAL USES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2010-04-15 WO disclosed
EP-1465880-B1 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE TO TREAT DISORDERS ASSOCIATED WITH SOMATOSTATINE IPSEN PHARMA (FR) 2009-08-05 EP disclosed
WO-2008047883-A1 PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-04-24 WO disclosed
EP-1318980-B1 HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS NOVARTIS AG (CH) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR HTR1D 4601/4885HTR2A 4338/4885MTNR1A 2591/4885
US-20110086001-A1 COMPLIANT BIOCOMPATIBLE POLYMER COMPOSITIONS FOR MEDICAL USES BMP2, ECPAS, PLOD3 HTR1D 4593/4885HTR2A 4334/4885MTNR1A 3481/4885
US-20220204497-A1 NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME TPX2, AIMP2, CDYL2 HTR1D 4595/4885HTR2A 3688/4885MTNR1A 3735/4885
US-20100228343-A1 PHASE-SEPARATED BIOCOMPATIBLE POLYMER COMPOSITIONS FOR MEDICAL USES BMP2, PUF60, MYADM HTR1D 4554/4885HTR2A 4496/4885MTNR1A 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.